Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

Stock Information for Talaris Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Talaris Therapeutics Inc.

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
SHAREHOLDER ALERT: Morris Kandinov Investigating AEL, CPRI, TALS, and PFSW; Shareholders are Encouraged to Contact the Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates APRN, RENB, TALS, WMC
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, TALS, QUOT
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - TALS, QUOT, NEWR, EMAN

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.